Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CP-675, 206 and gemcitabine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CP-675,206 and gemcitabine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CP-675,206 and gemcitabine | DRUG | Escalating doses of CP-675,206 will be administered by IV infusion on day 1 of each 84-day treatment cycles (doses of 6, 10 and 15 mg/kg are planned). Gemcitabine will be administered by IV infusion, at a fixed dose of 1000 mg/m2 on days 1 (prior to CP-675,206) and again on days 8, 15, 29, 36, 43, 57, 64, and 71. Repeated cycles of gemcitabine and CP-675,206 will be administered until patients develop progressive disease or unacceptable toxicity, or for a maximum of 4 cycles, whichever occurs first. |
Inclusion Criteria: * Patients with metastatic pancreatic cancer * Patient must have adequate bone marrow, liver and kidney function * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 * Chemotherapy naive * Inoperable pancreatic cancer Exclusion Criteria: ...
Top 20 of 68 competitors
CP-675,206 is an investigational oncology therapy being studied in prostatic neoplasms, melanoma, pancreatic cancer, renal cell carcinoma, non-small-cell lung cancer, and colorectal neoplasms. It is a small molecule being developed by AstraZeneca PLC and is currently in Phase 2 clinical development.
CP-675,206 is a small molecule oncology therapy. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being investigated across multiple solid tumor types including melanoma, renal cell carcinoma, and non-small-cell lung cancer.
CP-675,206 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The drug is currently in Phase 2 clinical trials for multiple oncology indications.
CP-675,206 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials have been completed, along with two Phase 1 trials, with a total enrollment of 740 patients across all studies.
CP-675,206 has completed two Phase 2 trials: NCT00086489 in advanced melanoma and NCT00312975 in non-small-cell lung cancer. Two Phase 1 trials, NCT00372853 in metastatic renal cell carcinoma and NCT00431275 in melanoma, have also been completed. All trials are closed.
CP-675,206 is an investigational monoclonal antibody being developed by AstraZeneca. While it has been studied in oncology indications, no alternative names have been established in the clinical trial records. The drug remains in Phase 2 development.